Companies Dominating the Antihemophilic Factor Landscape
- Genetech
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Biogen Idec
- Bayer AG
- Octapharma
- Novo Nordisk
- Baxter
- Kedrion
- Pfizer Inc.
- Sanofi SA
- CSL Behring
Browse Key Market Insights with Data Illustration:
In the News
- Sanofi’s fitusiran, an innovative small interfering RNA (sIRNA) therapy, has successfully completed two phases 3 trials, demonstrating a significant decrease in annualized bleeding rates in hemophilia A or B patients, meeting its primary objective.
- Bayer AG has ceased the production of kogenate, a previously FDA-approved treatment for hemophilia A.
